Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies
First-in-human CROSSCHECK-001 study marks company’s entry into the clinic with novel T-Bolt™
T-cell engager (TCE)
CAMBRIDGE, Mass., September 16, 2025 – Crossbow Therapeutics, Inc., a biotechnology
company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics, today
announced dosing of the first participant in its CROSSCHECK-001 Phase 1 clinical trial of CBX-
250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid
malignancies.
“Patients with relapsed or refractory myeloid malignancies urgently need new treatment
options, and CBX-250 offers a novel approach,” said Briggs Morrison, M.D., Chief Executive
Officer of Crossbow. “The preclinical profile of CBX-250 and its novel targeting strategy bolster
our confidence as we begin to bring the expansive potential of our T-Bolt™ platform to
patients.”
CBX-250 is the first candidate developed through Crossbow’s T-Bolt™ platform, a portfolio of
novel TCE molecules that uniquely target peptide-loaded human leukocyte antigen (pHLA)
complexes on tumor cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Specifically, CBX-250 targets a cathepsin G pHLA complex, abundantly expressed on leukemic
cells, but not normal cells. The Phase 1, open-label, dose-escalation CROSSCHECK-001 study is
the first clinical trial for Crossbow and the T-Bolt™ platform. The study is evaluating the safety,
tolerability, and preliminary clinical activity of CBX-250 in patients aged 12 years and older with
relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-
MDS), and chronic myelomonocytic leukemia (CMML).
AML, one of the most common myeloid malignancies, is primarily a disease of older adults, with
an average patient age of 68 years. In the United States, the estimated incidence of AML
exceeds 22,000 new cases each year, and the five-year survival rate is approximately 33%. 1 In
AML patients, relapse is common within the first year of achieving complete remission,
occurring in more than 50% of patients after induction chemotherapy, the current standard of
care. 2 Those with relapsed or refractory AML have an especially poor prognosis, underscoring
the urgent need for potent therapies directed against novel tumor-selective therapeutic
targets.
CBX-250 was developed through an ongoing strategic collaboration between Crossbow and The
University of Texas MD Anderson Cancer Center. Crossbow designed and is conducting the
CROSSCHECK‑001 clinical study, which is investigating CBX-250 on a fixed step-up dosing
schedule. The company expects initial clinical data from CROSSCHECK-001 in 2026.
For additional trial details, visit the CROSSCHECK-001 study page on ClinicalTrials.gov.
About Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of
people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic
antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled
immunotherapies directed with high precision at previously unreachable cancer cell targets.
Crossbow’s efficient and selective approach is designed to target the entire universe of cancer
proteins, dramatically expanding the potential of antibody therapy to address many types of
cancer. For more information about Crossbow Therapeutics, visit www.crossbowtx.com.
Investor Contact:
Crossbow Therapeutics, Inc.
Geraldine Paulus, Co-Founder, Head of Corporate Development and Operations
Geraldine.paulus@crossbowtx.com
Media Contact:
SmithSolve
Corey Carmichael
(862) 260-7929
Corey.carmichael@smithsolve.com
—
1 Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). U.S. Department of Health and Human Services, National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program; 2025.
https://seer.cancer.gov/statfacts/html/amyl.html. Accessed July 7, 2025.
2 Farhad R, Roland B.W., Sylvie D.F.; Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv 2018; 2 (11): 1356–1366. https://doi.org/10.1182/bloodadvances.2018016378